Last $5.64 USD
Change Today -0.23 / -3.92%
Volume 1.8M
OREX On Other Exchanges
Symbol
Exchange
NASDAQ GS
Stuttgart
As of 8:10 PM 02/27/15 All times are local (Market data is delayed by at least 15 minutes).

orexigen therapeutics inc (OREX) Snapshot

Open
$5.86
Previous Close
$5.87
Day High
$5.86
Day Low
$5.60
52 Week High
03/19/14 - $7.82
52 Week Low
10/13/14 - $3.11
Market Cap
697.8M
Average Volume 10 Days
1.6M
EPS TTM
$-0.35
Shares Outstanding
123.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for OREXIGEN THERAPEUTICS INC (OREX)

orexigen therapeutics inc (OREX) Related Businessweek News

View More BusinessWeek News

orexigen therapeutics inc (OREX) Details

Orexigen Therapeutics, Inc., a biopharmaceutical company, focuses on the development of pharmaceutical product candidates for the treatment of obesity. Its product candidates include NB32, which has completed Phase III clinical trials and is being studied in a cardiovascular outcomes trial; and Empatic that has completed Phase II clinical trials. Orexigen Therapeutics, Inc. has collaboration agreement with Takeda Pharmaceutical Company Limited to develop and commercialize NB32 in the United States, Canada, and Mexico. The company was founded in 2002 and is headquartered in La Jolla, California.

orexigen therapeutics inc (OREX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $625.0K
Acting Chief Financial Officer, Principal Acc...
Total Annual Compensation: $370.0K
Senior Vice President, General Counsel and Se...
Total Annual Compensation: $370.0K
Head of Global Contrave Program and Senior Vi...
Total Annual Compensation: $370.0K
Chief Commercial Officer
Total Annual Compensation: $296.0K
Compensation as of Fiscal Year 2013.

orexigen therapeutics inc (OREX) Key Developments

Orexigen Therapeutics, Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014

Orexigen Therapeutics, Inc. reported unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the three months ended December 31, 2014, the company reported a net profit of $0.6 million, or $0.00 per basic and diluted share, as compared to a net loss of $21.5 million, or $0.21 per basic and diluted share, for the fourth quarter of 2013. Total revenues were $22,950,000 compared to $857,000 a year ago. Income from operations was $2,385,000 compared to loss from operations of $20,956,000 a year ago. For the year ended December 31, 2014, the company reported a net loss of $37.5 million, or $0.32 per basic and diluted share, as compared to a net loss of $77.7 million, or $0.80 per basic and diluted share, for 2013. Total revenues were $55,521,000 compared to $3,428,000 a year ago. Loss from operations was $30,530,000 compared to $77,198,000 a year ago.

Orexigen Therapeutics, Inc. Presents at RBC Capital Markets Healthcare Conference 2015, Feb-25-2015 01:35 PM

Orexigen Therapeutics, Inc. Presents at RBC Capital Markets Healthcare Conference 2015, Feb-25-2015 01:35 PM. Venue: The New York Palace Hotel, New York, New York, United States. Speakers: Michael A. Narachi, Chief Executive Officer, President and Director.

Orexigen Therapeutics, Inc. Presents at Biocom's Global Life Science Partnering Conference, Feb-25-2015

Orexigen Therapeutics, Inc. Presents at Biocom's Global Life Science Partnering Conference, Feb-25-2015 . Venue: The Lodge at Torrey Pines, 11480 North Torrey Pines Road, La Jolla, CA 92037, United States.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OREX:US $5.64 USD -0.23

OREX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for OREX.
View Industry Companies
 

Industry Analysis

OREX

Industry Average

Valuation OREX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 13.0x
Price/Book 32.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 7.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OREXIGEN THERAPEUTICS INC, please visit www.orexigen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.